Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

IV dosing during 21- or 28-day cycles. Dosage per cohort will increase to determine the maximum tolerable dose.

IV dosing during 21- or 28-day cycles. Subjects will be dosed at levels previously declared tolerable.

IV dosing during 21- or 28-day cycles. Subjects will be dosed at preliminary recommended phase 2 dose (RP2D).

JANX007 is dosed via IV in a 21- or 28-day cycle.

JANX007

Janux Therapeutics

Janux Therapeutics, MD

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate cancer (mCRPC).

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Time from documentation of complete response or partial response to disease progression using RECIST v1.1 and PCWG3

Time from treatment initiation to radiographic evidence of disease progression using RECIST v1.1 and PCWG3

Proportion of participants who achieve a complete response or partial response using RECIST v1.1 and PCWG3

Time from treatment initiation until death from any cause

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)	NCT05519449	Prostate Cancer Metastatic Cast... Castration Resi...	JANX007	18 Years - 100 Years	Janux Therapeutics
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)	NCT05519449	Prostate Cancer Metastatic Cast... Castration Resi...	JANX007	18 Years - 100 Years	Janux Therapeutics

Spots Global Cancer Trial Database for janx007

Every month we try and update this database with for janx007 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for janx007

Every month we try and update this database with for janx007 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for janx007 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.